Key Differences Between DESTINY-Breast04 and DESTINY-Breast06 Trials
DESTINY-Breast06 (DB-06) enrolled patients earlier in their treatment course—after endocrine therapy but before any chemotherapy for metastatic disease—while DESTINY-Breast04 (DB-04) required patients to have received 1-2 prior lines of chemotherapy in the metastatic setting. This fundamental difference in patient population makes DB-06 a study of earlier-line therapy compared to DB-04 1, 2, 3.
Patient Population Differences
Prior Treatment Requirements
DB-04 enrolled patients who had:
- Received 1-2 prior lines of chemotherapy for metastatic disease, OR
- Experienced progression within 6 months of (neo)adjuvant chemotherapy
- 70% had received prior CDK4/6 inhibitor therapy 4, 2
DB-06 enrolled patients who had:
- Received ≥1 line of endocrine-based therapy for metastatic disease (median of 2 lines)
- No prior chemotherapy for metastatic disease (chemotherapy-naive in the metastatic setting)
- 89% had received prior CDK4/6 inhibitor therapy
- 41% had prior taxane use in the non-metastatic (adjuvant/neoadjuvant) setting 1, 3
HER2 Expression Categories
DB-04 included only:
- HER2-low patients (IHC 1+ or IHC 2+/ISH-negative)
- 88.7% hormone receptor-positive, 11.3% hormone receptor-negative (TNBC) 2
DB-06 expanded to include:
- HER2-low patients (IHC 1+ or IHC 2+/ISH-negative): 713 patients (82%)
- HER2-ultralow patients (IHC 0 with membrane staining): 153 patients (18%)
- All patients were hormone receptor-positive 1, 3
Study Design Differences
Randomization and Sample Size
- DB-04: 2:1 randomization (T-DXd vs physician's choice), 557 total patients 2
- DB-06: 1:1 randomization (T-DXd vs physician's choice), 866 total patients 1, 3
Control Arm Composition
DB-04 physician's choice included:
- Eribulin, capecitabine, gemcitabine, paclitaxel, or nab-paclitaxel 2
DB-06 physician's choice included:
- Capecitabine (60%), nab-paclitaxel (24%), or paclitaxel (16%) 1
Efficacy Outcomes
Progression-Free Survival
DB-04 (hormone receptor-positive cohort):
- T-DXd: 10.1 months
- Physician's choice: 5.4 months
- HR 0.51 2
DB-06 (HER2-low population):
The longer PFS in DB-06 reflects the less heavily pretreated population and earlier line of therapy.
Overall Survival
DB-04 (hormone receptor-positive cohort):
DB-06: OS data were immature at the time of primary analysis (only 39% of patients had died) 1, 3
Clinical Implications
The DB-06 trial establishes T-DXd as an option immediately after endocrine therapy failure, without requiring prior chemotherapy for metastatic disease 4. This represents a significant shift toward earlier use compared to DB-04, which positioned T-DXd after 1-2 lines of chemotherapy 4.
DB-06 also validated T-DXd activity in the HER2-ultralow population (IHC 0 with membrane staining), expanding the eligible patient population beyond the traditional HER2-low definition used in DB-04 1, 3, 6, 7.
Treatment Sequencing Considerations
Based on DB-04, T-DXd should be prioritized over sacituzumab govitecan (SG) in HER2-low hormone receptor-positive disease because it was studied in a less pretreated population 4. DB-06 further reinforces this by demonstrating efficacy even earlier in the treatment course, before any chemotherapy for metastatic disease 1, 3.
For triple-negative breast cancer (TNBC), DB-04 included only 58 patients with HER2-low TNBC as an exploratory cohort, whereas DB-06 excluded TNBC entirely (only hormone receptor-positive patients) 4, 1.